-
1.发明申请公开(公告)号：US20250049919A1
公开(公告)日：2025-02-13
申请号：US18785059
申请日：2024-07-26
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas Ichim , Courtney Bartlett , Timothy Warbington , Amit Patel
IPC: A61K39/00 , C12N5/0775
Abstract: Compositions of matter and treatment protocols for reducing or completely avoiding the need for immune suppression in the context of allograft or xenograft transplantation. Use of mesenchymal stem cells, manipulated mesenchymal stem cells, iPSC derived mesenchymal stem cells, and products of said mesenchymal stem cells for promoting the process of immunological tolerance. In one embodiment the invention provides the use of third party “universal donor” iPSC gene edited mesenchymal stem cells to promote tolerance in context of a solid organ transplant such as renal, cardiac, hepatic or small intestine. In other embodiments endogenous mesenchymal stem cells in composite tissue allografts are activated and/expanded in order to promote tolerogenesis and reduced need for immune suppression.
-
公开(公告)号：US20250049853A1
公开(公告)日：2025-02-13
申请号：US18794184
申请日：2024-08-05
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas Ichim , Courtney Bartlett , Timothy Warbington , Amit Patel
Abstract: Methods and compositions of matter useful for reducing extent of spinal cord injury and/or reversion of spinal cord injury gliosis are disclosed. T regulatory cells can be administered systemically and/or locally to a patient suffering from spinal cord injury. T regulatory cells can be modulated by engineering either through gene modification or culture conditions in order to augment regenerative/antifibrotic properties. Utilizing pluripotent stem cell derived T regulatory cells for spinal cord injury and chimeric antigen receptor T cells.
-
公开(公告)号：US20250027044A1
公开(公告)日：2025-01-23
申请号：US18775133
申请日：2024-07-17
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas Ichim , Courtney Bartlett , Timothy Warbington , Amit Patel
IPC: C12N5/0783
Abstract: Compositions of matter and means useful for treatment of autoimmunity and/or transplant rejection through generation of T regulatory cells in a manner that recapitulates thymic development. Methods of seeding thymic medullary epithelial cells with pluripotent stem cells such as inducible pluripotent stem cells, followed by exposure to conditions allowing for selective growth and expansion of T regulatory cells. T regulatory cells can be scaled for clinical utilization through the use of three-dimensional adhesive growth matrices as well as addition of FoxP3 inducing cytokines such as interleukin-2.
-
公开(公告)号：US20240374723A1
公开(公告)日：2024-11-14
申请号：US18646563
申请日：2024-04-25
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas Ichim , Amit Patel , Courtney Bartlett , Timothy Warbington
IPC: A61K39/00 , C12N5/0784
Abstract: The invention provides methods of inducing immunological tolerance to a transplanted cellular population or organ by creating and administering a “veto-like” cell originating from the identical genetic background of the organ donor. In one embodiment said artificially generated veto cell is a dendritic cell population possessing molecules associated with tolerance induced in natural anatomical locations such as the placenta, the testis, or the eye. In one embodiment dendritic cells resistant to maturation are generated from pluripotent stem cells that have been gene edited to lack genes needed for acquisition of antigen presenting properties such as relB, NF-kappa B and transporter associated protein. In another embodiment immature dendritic cells are gene edited/transfected to express tolerance associated molecules such as interleukin-10, interleukin-35, Fas ligand, TRAIL, TGF-beta, HLA-G and arginase.
-
5.发明公开公开(公告)号：US20240339176A1
公开(公告)日：2024-10-10
申请号：US18630510
申请日：2024-04-09
Applicant: Creative Medical Technologies, Inc.
Inventor： Thomas Ichim , Timothy Warbington , Amit Patel , Courtney Bartlett
Abstract: Disclosed are systems, means and compositions of matter utilizing artificial intelligence to create unique cells and/or organs from pluripotent stem cells. In one embodiment an artificial intelligence/machine learning approach is utilized to overview and categorize molecular and cellular data regarding normal embryonic development and associated pathways. Through acquiring this information, said artificial intelligence/machine learning system develops a graded list of morphogens/differentiating agents and/or conditions that are utilized to replicate the process of cell/tissue/organ formation artificially. In one embodiment the invention teaches generation of artificial pancreatic organoids through growth factors predicted by said artificial intelligence/machine learning systems. In other embodiments embryogenesis is recapitulated in adult tissue using predicted morphogens and/or extracellular matrix treatments.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20230399626A1
公开(公告)日：2023-12-14
申请号：US18331048
申请日：2023-06-07
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC: C12N5/071
CPC classification number: C12N5/0692 , C12N2501/60
Abstract: Disclosed are means, methods and compositions of matter useful for generation of conditioned media from endothelial progenitor cells (EPC). In one embodiment, EPC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the EPC lineage. The differentiated EPC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment EPC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.
-
公开(公告)号：US20230374463A1
公开(公告)日：2023-11-23
申请号：US18311768
申请日：2023-05-03
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC: C12N5/0775
CPC classification number: C12N5/0662 , C12N2506/45 , C12N2500/02
Abstract: Disclosed are compositions of matter, protocols, and procedures useful for generation of mesenchymal stem cells capable of withstanding the microenvironment of degenerating ovaries. In one embodiment mesenchymal stem cells are pre-treated under conditions capable of upregulating cytoprotective responses and genes, such as HIF-1 alpha and hemoxygenase. In other embodiments mesenchymal stem cells are temporarily pulsed with hypoxia and/or acidity in order to prime them for the harsh environment of degenerating ovarian tissue. Through this approach increased viability of mesenchymal stem cell subsequent to intra-ovarian administration is achieved.
-
公开(公告)号：US20230366876A1
公开(公告)日：2023-11-16
申请号：US18315364
申请日：2023-05-10
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
CPC classification number: G01N33/5044 , A61K35/28
Abstract: Disclosed are means and methods useful in selecting osteoarthritis patients most likely to respond to regenerative medicine therapy. One means of practicing the invention is to determine quantity and quality of inflammatory exosomes generated from the tissue adjacent to the injured cartilage. In another embodiment the invention provides detection of exosomes produced by inflammatory processes local or systemic to the body. In some embodiments therapies are tailored to the extent of inflammatory exosomes.
-
公开(公告)号：US20230365930A1
公开(公告)日：2023-11-16
申请号：US18311457
申请日：2023-05-03
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC: C12N5/0783
CPC classification number: C12N5/0636 , C12N2501/71
Abstract: Disclosed are methods, protocols and compositions of matter using for treatment of ovarian failure through administration of cells expressing FoxP3 as a monotherapy or as a facilitator to enhance therapeutic efficacy of cells and/or cytokines. In one embodiment FoxP3 expressing cells are concentrated from allogeneic umbilical cord blood, activated ex vivo with anti-CD3 and anti-CD28 antibodies and administered into the ovary alone or with regenerative cells such as stem cells. In one embodiment stem cells administered are of the CD105 expressing lineage.
-
公开(公告)号：US20230364143A1
公开(公告)日：2023-11-16
申请号：US18311464
申请日：2023-05-03
Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventor： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC: A61K35/17 , C12N5/0783 , C12N15/113
CPC classification number: A61K35/17 , C12N5/0637 , C12N15/1138 , C12N2502/1121 , C12N2310/11 , C12N2310/14 , C12N2502/1352 , C12N2501/115 , C12N2501/135
Abstract: Disclosed are compositions of matter, protocols and procedures useful for preventing/treatment ovarian failure. In one embodiment cytokines promoting anti-inflammatory/regenerative activity are administered systemically, or locally in order to preventing ovarian degeneration/fibrosis. In one embodiment low dose interleukin-2 is administered either alone or with adjuvant cytokines to induce an increase in FoxP3 expressing CD4 cells. In some embodiments in vivo generation of FoxP3 expressing CD4 cells is associated with stimulation of intra-ovarian angiogenesis and prevention of fibrosis.
-
-
-
-
-
-
-
-
-
Search Results
62
records
(took 0.029 seconds)
